ClinicalTrials.gg
CompletedNCT02597933Updated Dec 13, 2019Results posted

A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis

A Phase 3 interventional study of Nintedanib and Placebo in Scleroderma, Systemic, sponsored by Boehringer Ingelheim. Completed at 195 sites in 32 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-13.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
580
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 165 studies in Scleroderma, Systemic with a site in United States — 40 open to participants now, 52 under way, 6 of them phase 3. Scleroderma, Systemic · United States.

Enrollment
2nd of 142
580 · median 34
Started
2015
with 6 others
Phase 3
12 of 165
3 open now
Registered
72nd of 165
by date

Among the 165 studies in Scleroderma, Systemic with a site in United States, this one is the 2nd largest by enrollment of the 142 interventional ones that give a count, is one of 7 that started in 2015, is one of 12 in phase 3, and was the 72nd registered.

Scleroderma, Systemic

613 studies on the registry are indexed under Scleroderma, Systemic; 221 are open to participants now.

Browse Scleroderma, Systemic studies →

Open to participants now

40 of the 165 studies in Scleroderma, Systemic with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 145 Scleroderma, Systemic studies recruiting now, 83 (57%) set no upper age limit and 49 (34%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 165 studies in Scleroderma, Systemic with a site in United States, or all of them as a file.
02

Study summary

Systemic Sclerosis (SSc) is a devastating disease of unknown etiology. Patients suffer from multiple organ fibrosis whereas lung fibrosis (interstitial lung disease, ILD) is one of the main driver for mortality. There is preclinical evidence for efficacy of nintedanib in SSc and associated ILD (SSc-ILD) and the anti-fibrotic efficacy of nintedanib was proven in idiopathic pulmonary fibrosis patients, who are presenting a similar pattern regarding lung fibrosis. Hence it is the purpose of the trial to confirm the efficacy and safety of nintedanib 150 mg bid in treating patients with SSc-ILD, compared with placebo. The trial will be conducted as a double blind, randomised, placebo-controlled trial with primary efficacy evaluation at week 52 and placebo-controlled treatment until last patient out (up to a maximum of 100 weeks). Respiratory function is globally accepted for assessment of treatment effects in patients with lung fibrosis. The chosen endpoint (Forced Vital Capacity (FVC) decline) is easy to obtain and is part of the usual examinations done in patients with SSc-ILD.

03

Conditions studied

  • Scleroderma, Systemic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >= 18 years
  • 2013 American College of Rheumatology (ACR) / EULAR classification criteria for SSc fulfilled
  • SSc disease onset (defined by first non-Raynaud symptom) within 7 years
  • SSc related Interstitial Lung Disease confirmed by High Resolution Computer Tomography (HRCT); Extent of fibrotic disease in the lung >= 10%
  • FVC >= 40% of predicted normal
  • Carbon Monoxide Diffusion Capacity (DLCO) 30% to 89% of predicted normal

Exclusion criteria

Exclusion criteria:

  • (AST), Alanine Aminotransferase (ALT) >1.5 x
  • >1.5 x ULN
  • \<30 mL/min
  • Airway obstruction (pre-bronchodilator (FEV1)/FVC \<0.7)
  • Other pulmonary abnormalities
  • Significant Pulmonary Hypertension (PH)
  • Cardiovascular diseases
  • More than 3 digital fingertip ulcers or a history of severe digital necrosis requiring hospitalization or severe other ulcers
  • Bleeding risk (such as predisposition to bleeding, fibrinolysis, full-dose anticoagulation, high dose antiplatelet therapy, history of hemorrhagic central nervous system (CNS) event within last year
  • (INR) >2, prolongation of prothrombin time (PT) and partial thromboplastin time (PTT) by >1.5 x ULN)
  • History of thrombotic event within last year
  • Clinical signs of malabsorption or needing parenteral nutrition
  • Previous treatment with nintedanib or pirfenidone
  • Treatment with prednisone >10 mg/day, azathioprine, hydroxychloroquine, colchicine, D-penicillamine, sulfasalazine, cyclophosphamide, rituximab, tocilizumab, abatacept, leflunomide, tacrolimus, newer anti-arthritic treatments like tofacitinib and cyclosporine A, potassium para-aminobenzoate
  • Unstable background therapy with either mycophenolate mofetil or methotrexate
  • Previous or planned hematopoietic stem cell transplantation
  • Patients with underlying chronic liver disease ( A, B, C hepatic impairment)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
580 participants (actual)

Study arms

  • Experimental
    Nintedanib

    patient receives capsules containing nintedanib twice a day

    Drug: Nintedanib

  • Placebo comparator
    Placebo

    patient receives capsules identical to those containing active drug

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks

    Forced vital capacity (FVC) is the total amount of air exhaled during the lung function test. For this endpoint reported means represent the adjusted rate.

    Time frame: up to week (wk) 52 after the start of administration

Secondary outcomes

  1. Absolute Change From Baseline in the Modified Rodnan Skin Score (mRSS) at Week 52

    This is the first key secondary endpoint. The modified Rodnan Skin Score (mRSS) is an evaluation of the patient's skin thickness rated by clinical palpation using a 0 to 3 scale. The scale differentiates between 0 = normal skin, 1 = mild thickness, 2 = moderate thickness, and 3 = severe thickness with inability to pinch the skin into a fold. The palpation is done for each of the 17 surface anatomic areas of the body: face, anterior chest, abdomen, fingers (right and left separately), forearms, upper arms, thighs, lower legs, dorsum of hands and feet. The sum of these individual values is defined as the total skin score. The mRSS has a range from 0 (no thickening) to 51 (severe thickening in all 17 areas). A high score corresponds to worse skin thickness. Least square mean is actually the adjusted mean. Adjusted mean was based on all analysed patients in the model (not only patients with a baseline and measurement at Week 52).

    Time frame: Baseline and up to 52 weeks after the start of administration

  2. Absolute Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Total Score at Week 52.

    This is the second key secondary endpoint. The Saint George's Respiratory Questionnaire measures the health status in patients with chronic airflow limitation. It consists of 2 parts that cover 3 domains: symptoms, activities, and impacts. The symptom domain relates to the effect, frequency and severity of respiratory symptoms. The activity domain relates to activities that cause or are limited by breathlessness. The impact domain evaluates a range of aspects concerned with social functioning and psychological disturbances resulting from airways disease. The scores of these domains range from 0 (no impairment) to 100 (worst possible). The calculated total score summarises the impact of the disease on overall health status. A high score corresponds to worse health. Least square mean is actually the adjusted mean. Adjusted mean was based on all analysed patients in the model (not only patients with a baseline and measurement at Week 52).

    Time frame: Baseline and up to 52 weeks after the start of administration

  3. Annual Rate of Decline in FVC in Percentage (%) Predicted Over 52 Weeks

    Annual rate of decline in FVC in percentage (%) predicted over 52 weeks. For this endpoint reported means represent the adjusted rate.

    Time frame: up to 52 weeks after the start of administration

  4. Absolute Change From Baseline in FVC in mL at Week 52

    Absolute change from baseline in FVC in mL at Week 52. Least square mean is actually the adjusted mean. Adjusted mean was based on all analysed patients in the model (not only patients with a baseline and measurement at Week 52).

    Time frame: Baseline and up to 52 weeks after the start of administration

  5. Relative Change From Baseline [%] of mRSS at Week 52

    Relative change from baseline \[%\] of mRSS at Week 52. The modified Rodnan Skin Score (mRSS) is an evaluation of the patient's skin thickness rated by clinical palpation using a 0 to 3 scale. The scale differentiates between 0 = normal skin, 1 = mild thickness, 2 = moderate thickness, and 3 = severe thickness with inability to pinch the skin into a fold. The palpation is done for each of the 17 surface anatomic areas of the body: face, anterior chest, abdomen, fingers (right and left separately), forearms, upper arms, thighs, lower legs, dorsum of hands and feet. The sum of these individual values is defined as the total skin score. The mRSS has a range from 0 (no thickening) to 51 (severe thickening in all 17 areas). A high score corresponds to worse skin thickness. Least square mean is actually the adjusted mean. Adjusted mean was based on all analysed patients in the model (not only patients with a baseline and measurement at Week 52).

    Time frame: Baseline and up to 52 weeks after the start of administration

  6. Time to Death

    Time to event analysis of patients with death. The number of observed patients with death are reported.

    Time frame: From date of first trial drug intake up to date of death or last contact date (ie., up to 100 weeks)

  7. The Percentage (%) of Responder Based on Combined Response Index in Systemic Sclerosis (CRISS) at Week 52

    The percentage (%) of responder based on Combined Response Index in Systemic Sclerosis (CRISS) at Week 52. This is a composite endpoint, based on the mRSS, FVC percent predicted, HAQ-DI, patient's global impression of overall health Visual Analogue Scale (VAS) and physician's global impression of patient's overall health VAS, as well as the absence of significant worsening of interstitial lung disease, a new scleroderma renal crisis, left ventricular failure or pulmonary arterial hypertension. The CRISS index score represents a probability of improvement and ranges between 0 and 1. This is a 2 stage process to predict probability of improvement: Step 1 - absence of major organ progression (SRC etc.) - score "0" Step 2 - predicted probability of improvement - (score "0 - 1")

    Time frame: Week 52

  8. Absolute Change From Baseline in Carbon Monoxide Diffusion Capacity (DLco) in % Predicted at Week 52

    Absolute change from baseline in Carbon Monoxide Diffusion Capacity (DLco) in % predicted at Week 52. Least square mean is actually the adjusted mean. Adjusted mean is based on all analysed patients in the model (not only patients with a baseline and measurement at week 52).

    Time frame: Baseline and up to 52 weeks after the start of administration

  9. Absolute Change From Baseline in Digital Ulcer Net Burden at Week 52

    Absolute change from baseline in digital ulcer net burden (defined as the number of new digital ulcers (DUs) plus the number of DUs that have been verified at any earlier assessment during the trial) at Week 52. It is calculated at a visit by counting the total number of fingertips with ulcers (i.e. number of fingers with presence of digital ulcer ticked "Yes") at the corresponding visit Least square mean is actually the adjusted mean. Adjusted mean is based on all analysed patients in the model (not only patients with a baseline and measurement at week 52).

    Time frame: Baseline and up to 52 weeks after the start of administration

  10. Absolute Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 52

    Absolute change from baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) score at Week 52. The HAQ-DI score is calculated as follows: Each question is scored 0-3 (where 0= "without difficulty" \& 3= "unable to do"). There are 8 categories (Dressing \& Grooming, Arising, Eating, Walking, Hygiene, Reach, Grip, Activities), each including 2 or 3 questions. The score for each category corresponds to maximum question score within each category. Finally, HAQ-DI score corresponds to sum of the sub-scores of all 8 categories divided by number of categories completed. Please note that if there are fewer than 6 categories with responses, then a score cannot be calculated. The HAQ-DI score scale has 25 possible values (i.e., 0, 0.125, 0.250, 0.375 ... 3). A high score corresponds to worse impairment. Least square mean is actually the adjusted mean. Adjusted mean is based on all analysed patients in the model (not only patients with a baseline and measurement at week 52).

    Time frame: Baseline and up to 52 weeks after the start of administration

  11. Absolute Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Dyspnoea Score at Week 52

    Absolute change from baseline in Functional Assessment of Chronic Illness Therapy (FACIT) dyspnoea score at Week 52. FACIT-Dyspnoea (Dyspnoea) 10 Item Short Form include a 4-point rating scale (no shortness of breath=0; mildly short of breath=1; moderately short of breath = 2; severely short of breath =3; or I did not do this in the past 7 days =4). A raw score is calculated as: Sum individual item scores \* 10 / number of items answered. Raw scores are then converted to scale scores using the table included in the FACIT Dyspnoea Scale Short Form Scoring Guideline. FACIT dyspnea scale score ranges between 0 and 75.9. The FACIT-Dyspnea short forms are scored such that a high score represents high levels of dyspnea. Least square mean is actually the adjusted mean. Adjusted mean is based on all analysed patients in the model (not only patients with a baseline and measurement at week 52).

    Time frame: Baseline and up to 52 weeks after the start of administration

07

Results

Posted Dec 13, 2019

Participant flow

This was a randomised, placebo-controlled, double-blind, parallel design trial. Abbreviation used: treatment (trt) baseline (bl.) categorical (cat.) continuous (cont.) number (no.) patient (pt) Placebo (pl.) discontinued (disc.) primary analysis (PA) Antitopoisomerase Antibody (ATA)

Participant flow — Overall Study
MilestonePlaceboNintedanib
Started290290
Treated patients288288
Completed252239
Not completed3851
Withdrew: Withdrawal by subject75
Withdrew: Protocol violation22
Withdrew: Adverse event2028
Withdrew: Not treated22
Withdrew: Other than stated above714

Outcome measures

PrimaryAnnual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks

Forced vital capacity (FVC) is the total amount of air exhaled during the lung function test. For this endpoint reported means represent the adjusted rate.

Time frame:
up to week (wk) 52 after the start of administration
Reported as:
Mean · millilitre (mL)/year (yr)
Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks
millilitre (mL)/year (yr)PlaceboNintedanib
Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks-93.3 ± 13.5-52.4 ± 13.8
Statistical analysis
  • Placebo vs Nintedanib · random coefficient regression · p = 0.0350 · Mean difference (final values): 40.95 · 95% CI 2.88 to 79.01The model assumed that data were missing at random \& that patients who dropped out would have behaved similarly to those who remained in trial.
  • Placebo vs Nintedanib · random coefficient regression · p = 0.0378 · Mean difference (final values): 43.13 · 95% CI 2.44 to 83.83The model assumed that data were missing at random \& that patients who dropped out would have behaved similarly to those who remained in trial.
  • Placebo vs Nintedanib · random coefficient regression · p = 0.1046 · Mean difference (final values): 30.00 · 95% CI -6.22 to 66.22
  • Placebo vs Nintedanib · random coefficient regression · p = 0.0740 · Mean difference (final values): 32.93 · 95% CI -3.19 to 69.06
  • Placebo vs Nintedanib · random coefficient regression · p = 0.0644 · Mean difference (final values): 33.86 · 95% CI -2.03 to 69.75
  • Placebo vs Nintedanib · random coefficient regression · p = 0.0351 · Mean difference (final values): 40.95 · 95% CI 2.88 to 79.01
  • Placebo vs Nintedanib · random coefficient regression · p = 0.0349 · Mean difference (final values): 40.98 · 95% CI 2.92 to 79.04
SecondaryAbsolute Change From Baseline in the Modified Rodnan Skin Score (mRSS) at Week 52

This is the first key secondary endpoint. The modified Rodnan Skin Score (mRSS) is an evaluation of the patient's skin thickness rated by clinical palpation using a 0 to 3 scale. The scale differentiates between 0 = normal skin, 1 = mild thickness, 2 = moderate thickness, and 3 = severe thickness with inability to pinch the skin into a fold. The palpation is done for each of the 17 surface anatomic areas of the body: face, anterior chest, abdomen, fingers (right and left separately), forearms, upper arms, thighs, lower legs, dorsum of hands and feet. The sum of these individual values is defined as the total skin score. The mRSS has a range from 0 (no thickening) to 51 (severe thickening in all 17 areas). A high score corresponds to worse skin thickness. Least square mean is actually the adjusted mean. Adjusted mean was based on all analysed patients in the model (not only patients with a baseline and measurement at Week 52).

Time frame:
Baseline and up to 52 weeks after the start of administration
Reported as:
Least squares mean · unit on scale
Absolute Change From Baseline in the Modified Rodnan Skin Score (mRSS) at Week 52
unit on scalePlaceboNintedanib
Absolute Change From Baseline in the Modified Rodnan Skin Score (mRSS) at Week 52-1.96 ± 0.26-2.17 ± 0.27
Statistical analysis
  • Placebo vs Nintedanib · MMRM · p = 0.5785 · Mean difference (final values): -0.21 · 95% CI -0.94 to 0.53
SecondaryAbsolute Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Total Score at Week 52.

This is the second key secondary endpoint. The Saint George's Respiratory Questionnaire measures the health status in patients with chronic airflow limitation. It consists of 2 parts that cover 3 domains: symptoms, activities, and impacts. The symptom domain relates to the effect, frequency and severity of respiratory symptoms. The activity domain relates to activities that cause or are limited by breathlessness. The impact domain evaluates a range of aspects concerned with social functioning and psychological disturbances resulting from airways disease. The scores of these domains range from 0 (no impairment) to 100 (worst possible). The calculated total score summarises the impact of the disease on overall health status. A high score corresponds to worse health. Least square mean is actually the adjusted mean. Adjusted mean was based on all analysed patients in the model (not only patients with a baseline and measurement at Week 52).

Time frame:
Baseline and up to 52 weeks after the start of administration
Reported as:
Least squares mean · unit on scale
Absolute Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Total Score at Week 52.
unit on scalePlaceboNintedanib
Absolute Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Total Score at Week 52.-0.88 ± 0.870.81 ± 0.88
Statistical analysis
  • Placebo vs Nintedanib · MMRM · p = 0.1711 · Mean difference (final values): 1.69 · 95% CI -0.73 to 4.12The MMRM model assumed that data were missing at random \& that patients who dropped out would have behaved similarly to those who remained in trial.
SecondaryAnnual Rate of Decline in FVC in Percentage (%) Predicted Over 52 Weeks

Annual rate of decline in FVC in percentage (%) predicted over 52 weeks. For this endpoint reported means represent the adjusted rate.

Time frame:
up to 52 weeks after the start of administration
Reported as:
Mean · % predicted/yr
Annual Rate of Decline in FVC in Percentage (%) Predicted Over 52 Weeks
% predicted/yrPlaceboNintedanib
Annual Rate of Decline in FVC in Percentage (%) Predicted Over 52 Weeks-2.6 ± 0.4-1.4 ± 0.4
Statistical analysis
  • Placebo vs Nintedanib · MMRM · p = 0.0331 · Mean difference (final values): 1.15 · 1.15% CI 0.09 to 2.21The model assumed that data were missing at random \& that patients who dropped out would have behaved similarly to those who remained in trial.
SecondaryAbsolute Change From Baseline in FVC in mL at Week 52

Absolute change from baseline in FVC in mL at Week 52. Least square mean is actually the adjusted mean. Adjusted mean was based on all analysed patients in the model (not only patients with a baseline and measurement at Week 52).

Time frame:
Baseline and up to 52 weeks after the start of administration
Reported as:
Least squares mean · mL
Absolute Change From Baseline in FVC in mL at Week 52
mLPlaceboNintedanib
Absolute Change From Baseline in FVC in mL at Week 52-101.03 ± 13.62-54.63 ± 13.94
Statistical analysis
  • Placebo vs Nintedanib · MMRM · p = 0.0177 · Mean difference (final values): 46.41 · 95% CI 8.09 to 84.73The model assumed that data were missing at random \& that patients who dropped out would have behaved similarly to those who remained in trial.
SecondaryRelative Change From Baseline [%] of mRSS at Week 52

Relative change from baseline \[%\] of mRSS at Week 52. The modified Rodnan Skin Score (mRSS) is an evaluation of the patient's skin thickness rated by clinical palpation using a 0 to 3 scale. The scale differentiates between 0 = normal skin, 1 = mild thickness, 2 = moderate thickness, and 3 = severe thickness with inability to pinch the skin into a fold. The palpation is done for each of the 17 surface anatomic areas of the body: face, anterior chest, abdomen, fingers (right and left separately), forearms, upper arms, thighs, lower legs, dorsum of hands and feet. The sum of these individual values is defined as the total skin score. The mRSS has a range from 0 (no thickening) to 51 (severe thickening in all 17 areas). A high score corresponds to worse skin thickness. Least square mean is actually the adjusted mean. Adjusted mean was based on all analysed patients in the model (not only patients with a baseline and measurement at Week 52).

Time frame:
Baseline and up to 52 weeks after the start of administration
Reported as:
Least squares mean · percent change
Relative Change From Baseline [%] of mRSS at Week 52
percent changePlaceboNintedanib
Relative Change From Baseline [%] of mRSS at Week 52-3.92 ± 5.89-10.20 ± 5.98
Statistical analysis
  • Placebo vs Nintedanib · MMRM · p = 0.4547 · Mean difference (final values): -6.28 · 95% CI -22.77 to 10.21The model assumed that data were missing at random \& that patients who dropped out would have behaved similarly to those who remained in trial.
SecondaryTime to Death

Time to event analysis of patients with death. The number of observed patients with death are reported.

Time frame:
From date of first trial drug intake up to date of death or last contact date (ie., up to 100 weeks)
Reported as:
Count of participants · Participants
Time to Death
ParticipantsPlaceboNintedanib
Time to Death910
Statistical analysis
  • Placebo vs Nintedanib · Regression, Cox · p = 0.7535 · Hazard ratio (hr): 1.16 · 95% CI 0.47 to 2.84Based on Cox's regression model (Wald test), stratified by ATA status.
SecondaryThe Percentage (%) of Responder Based on Combined Response Index in Systemic Sclerosis (CRISS) at Week 52

The percentage (%) of responder based on Combined Response Index in Systemic Sclerosis (CRISS) at Week 52. This is a composite endpoint, based on the mRSS, FVC percent predicted, HAQ-DI, patient's global impression of overall health Visual Analogue Scale (VAS) and physician's global impression of patient's overall health VAS, as well as the absence of significant worsening of interstitial lung disease, a new scleroderma renal crisis, left ventricular failure or pulmonary arterial hypertension. The CRISS index score represents a probability of improvement and ranges between 0 and 1. This is a 2 stage process to predict probability of improvement: Step 1 - absence of major organ progression (SRC etc.) - score "0" Step 2 - predicted probability of improvement - (score "0 - 1")

Time frame:
Week 52
Reported as:
Number · (%) of responder based on CRISS
The Percentage (%) of Responder Based on Combined Response Index in Systemic Sclerosis (CRISS) at Week 52
(%) of responder based on CRISSPlaceboNintedanib
The Percentage (%) of Responder Based on Combined Response Index in Systemic Sclerosis (CRISS) at Week 5211.812.2
Statistical analysis
  • Placebo vs Nintedanib · Cochran-Mantel-Haenszel · p = 0.9115 · Odds ratio (or): 1.03 · 95% CI 0.57 to 1.88
SecondaryAbsolute Change From Baseline in Carbon Monoxide Diffusion Capacity (DLco) in % Predicted at Week 52

Absolute change from baseline in Carbon Monoxide Diffusion Capacity (DLco) in % predicted at Week 52. Least square mean is actually the adjusted mean. Adjusted mean is based on all analysed patients in the model (not only patients with a baseline and measurement at week 52).

Time frame:
Baseline and up to 52 weeks after the start of administration
Reported as:
Least squares mean · % predicted DLco
Absolute Change From Baseline in Carbon Monoxide Diffusion Capacity (DLco) in % Predicted at Week 52
% predicted DLcoPlaceboNintedanib
Absolute Change From Baseline in Carbon Monoxide Diffusion Capacity (DLco) in % Predicted at Week 52-2.77 ± 0.54-3.21 ± 0.54
Statistical analysis
  • Placebo vs Nintedanib · MMRM · p = 0.5668 · Mean difference (final values): -0.44 · 95% CI -1.94 to 1.06
SecondaryAbsolute Change From Baseline in Digital Ulcer Net Burden at Week 52

Absolute change from baseline in digital ulcer net burden (defined as the number of new digital ulcers (DUs) plus the number of DUs that have been verified at any earlier assessment during the trial) at Week 52. It is calculated at a visit by counting the total number of fingertips with ulcers (i.e. number of fingers with presence of digital ulcer ticked "Yes") at the corresponding visit Least square mean is actually the adjusted mean. Adjusted mean is based on all analysed patients in the model (not only patients with a baseline and measurement at week 52).

Time frame:
Baseline and up to 52 weeks after the start of administration
Reported as:
Least squares mean · fingers
Absolute Change From Baseline in Digital Ulcer Net Burden at Week 52
fingersPlaceboNintedanib
Absolute Change From Baseline in Digital Ulcer Net Burden at Week 520.06 ± 0.040.03 ± 0.05
Statistical analysis
  • Placebo vs Nintedanib · MMRM · p = 0.5914 · Mean difference (final values): -0.03 · 95% CI -0.16 to 0.09
SecondaryAbsolute Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 52

Absolute change from baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) score at Week 52. The HAQ-DI score is calculated as follows: Each question is scored 0-3 (where 0= "without difficulty" \& 3= "unable to do"). There are 8 categories (Dressing \& Grooming, Arising, Eating, Walking, Hygiene, Reach, Grip, Activities), each including 2 or 3 questions. The score for each category corresponds to maximum question score within each category. Finally, HAQ-DI score corresponds to sum of the sub-scores of all 8 categories divided by number of categories completed. Please note that if there are fewer than 6 categories with responses, then a score cannot be calculated. The HAQ-DI score scale has 25 possible values (i.e., 0, 0.125, 0.250, 0.375 ... 3). A high score corresponds to worse impairment. Least square mean is actually the adjusted mean. Adjusted mean is based on all analysed patients in the model (not only patients with a baseline and measurement at week 52).

Time frame:
Baseline and up to 52 weeks after the start of administration
Reported as:
Least squares mean · unit on a scale
Absolute Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 52
unit on a scalePlaceboNintedanib
Absolute Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 520.022 ± 0.0240.054 ± 0.024
Statistical analysis
  • Placebo vs Nintedanib · MMRM · p = 0.3447 · Mean difference (final values): 0.032 · 95% CI -0.035 to 0.099
SecondaryAbsolute Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Dyspnoea Score at Week 52

Absolute change from baseline in Functional Assessment of Chronic Illness Therapy (FACIT) dyspnoea score at Week 52. FACIT-Dyspnoea (Dyspnoea) 10 Item Short Form include a 4-point rating scale (no shortness of breath=0; mildly short of breath=1; moderately short of breath = 2; severely short of breath =3; or I did not do this in the past 7 days =4). A raw score is calculated as: Sum individual item scores \* 10 / number of items answered. Raw scores are then converted to scale scores using the table included in the FACIT Dyspnoea Scale Short Form Scoring Guideline. FACIT dyspnea scale score ranges between 0 and 75.9. The FACIT-Dyspnea short forms are scored such that a high score represents high levels of dyspnea. Least square mean is actually the adjusted mean. Adjusted mean is based on all analysed patients in the model (not only patients with a baseline and measurement at week 52).

Time frame:
Baseline and up to 52 weeks after the start of administration
Reported as:
Least squares mean · Unit on a scale
Absolute Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Dyspnoea Score at Week 52
Unit on a scalePlaceboNintedanib
Absolute Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Dyspnoea Score at Week 520.34 ± 0.410.99 ± 0.42
Statistical analysis
  • Placebo vs Nintedanib · MMRM · p = 0.2727 · Mean difference (final values): 0.64 · 95% CI -0.51 to 1.79

Adverse events

Collected over From date of first trial drug intake up to date of death or last contact date (ie., up to 100 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo9/288 (3.1%)79/288 (27.4%)239/288 (83%)
Nintedanib10/288 (3.5%)88/288 (30.6%)270/288 (93.8%)
Most frequent serious events
Showing 10 of 177
Most frequent serious events
EventPlaceboNintedanib
PneumoniaInfections and infestations2/28810/288
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders6/28810/288
DyspnoeaRespiratory, thoracic and mediastinal disorders8/2885/288
Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders4/2885/288
Systemic sclerosis pulmonaryRespiratory, thoracic and mediastinal disorders5/2883/288
Pulmonary arterial hypertensionRespiratory, thoracic and mediastinal disorders4/2884/288
Pulmonary fibrosisRespiratory, thoracic and mediastinal disorders4/2884/288
Atrial flutterCardiac disorders3/2880/288
Respiratory tract infectionInfections and infestations0/2883/288
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders3/2881/288
Most frequent other events
Showing 10 of 30
Most frequent other events
EventPlaceboNintedanib
DiarrhoeaGastrointestinal disorders92/288218/288
NauseaGastrointestinal disorders41/28896/288
VomitingGastrointestinal disorders31/28878/288
CoughRespiratory, thoracic and mediastinal disorders62/28841/288
NasopharyngitisInfections and infestations56/28843/288
Skin ulcerSkin and subcutaneous tissue disorders54/28856/288
Upper respiratory tract infectionInfections and infestations43/28839/288
Weight decreasedInvestigations15/28839/288
Abdominal painGastrointestinal disorders21/28836/288
HeadacheNervous system disorders28/28834/288

Baseline characteristics

Treated set (TS): The treated set consisted of patients who were randomised to a treatment group and received at least 1 dose of trial medication.

Age, Continuous
Age, Continuous(Years)PlaceboNintedanibTotal
Mean53.4 ± 12.654.6 ± 11.854.0 ± 12.2
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboNintedanibTotal
Female212221433
Male7667143
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboNintedanibTotal
Hispanic or Latino182240
Not Hispanic or Latino270266536
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboNintedanibTotal
American Indian or Alaska Native325
Asian8162143
Native Hawaiian or Other Pacific Islander011
Black or African American162036
White186201387
More than one race224
Unknown or Not Reported000
Baseline pulmonary efficacy variables - Forced Vital Capacity (FVC)
Baseline pulmonary efficacy variables - Forced Vital Capacity (FVC)(mL)PlaceboNintedanibTotal
Mean2541.0 ± 815.52458.5 ± 735.92499.7 ± 777.2
08

Study locations

195 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • University of California Los Angeles
    Los Angeles, California 90095, United States
  • University of California Davis
    Sacramento, California 95817, United States
  • University of California San Francisco
    San Francisco, California 94143, United States
  • Stanford University Medical Center
    Stanford, California 94305-5236, United States
  • University of Colorado Denver
    Aurora, Colorado 80045, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06510, United States
  • Georgetown University
    Washington, District of Columbia 20007, United States
  • University of Florida College of Medicine
    Jacksonville, Florida 32209, United States
  • University of Miami
    Miami, Florida 33125, United States
  • The Emory Clinic
    Atlanta, Georgia 30322, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • Tulane University Hospital and Clinic
    New Orleans, Louisiana 70112, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland 21224, United States
  • Boston Medical Center
    Boston, Massachusetts 02118, United States
  • University of Michigan Health System
    Ann Arbor, Michigan 48109, United States
  • University of Minnesota Masonic Cancer Center
    Minneapolis, Minnesota 55455, United States
  • Mayo Clinic-Rochester
    Rochester, Minnesota 55905, United States
  • The Lung Research Center, LLC
    Chesterfield, Missouri 63017, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Hospital for Special Surgery
    New York, New York 10021, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Columbia University Medical Center-New York Presbyterian Hospital
    New York, New York 10032, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • University of Cincinnati Health
    Cincinnati, Ohio 45219, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • University of Toledo
    Toledo, Ohio 43614, United States
  • Penn State Milton S. Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Temple University Hospital
    Philadelphia, Pennsylvania 19140, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • University of South Carolina
    Columbia, South Carolina 29203, United States
  • Vanderbilt Pulmonary Clinic
    Nashville, Tennessee 37232-5735, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • The University Of Texas at Houston
    Houston, Texas 77030, United States
  • University of Utah Health Sciences Center
    Salt Lake City, Utah 84108, United States
  • Inova Fairfax Medical Campus
    Falls Church, Virginia 22042, United States
  • Virginia Mason Medical Center
    Seattle, Washington 98101, United States
  • University of Washington
    Seattle, Washington 98195, United States
  • Froedtert and The Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich
    Buenos Aires, C1426BOR, Argentina
  • APRILLUS-Asistencia e Investigación
    Ciudad Autonoma Buenos Aires, C1046AAQ, Argentina
  • CEMER-Centro Medico De Enfermedades Respiratorias
    Florida, B1602DQD, Argentina
  • Royal Prince Alfred Hospital
    Camperdown, New South Wales 2050, Australia
  • Liverpool Hospital
    Sydney, New South Wales 2170, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • St Vincent's Hospital Melbourne
    Fitzroy, Victoria 3065, Australia
  • LKH-Univ. Hospital Graz
    Graz, 8036, Austria
  • Medical University of Innsbruck
    Innsbruck, 6020, Austria
  • ULB Hopital Erasme
    Bruxelles, 1070, Belgium
  • Brussels - UNIV Saint-Luc
    Bruxelles, 1200, Belgium
  • UNIV UZ Gent
    Gent, 9000, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • Centre Hospitalier Universitaire de Liège
    Liège, 4000, Belgium
  • Edumed - Educacao e Saude SA
    Curitiba, 80440-080, Brazil
  • Saint Joseph's Healthcare
    Hamilton, Ontario L8N 4A6, Canada
  • Mount Sinai Hospital
    Toronto, Ontario M5T 3L9, Canada
  • HSCM
    Montreal, Quebec H4J 1C5, Canada
  • Hospital Clínico Reg. de Concepción "Dr. G. Grant Benavente"
    Concepción, 4070038, Chile
  • Centro de Investigación del Maule
    Talca, 3465586, Chile
  • Peking Union Medical College Hospital
    Beijing, 100032, China
  • Beijing Chao-Yang Hospital
    Beijing, China
  • Beijing Hospital
    Beijing, China
  • First Hospital of Jilin University
    Changchun, China
  • West China Hospital
    Chengdu, 610041, China
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, 230022, China
  • Huashan Hospital, Fudan University
    Shanghai, 200040, China
  • The First Hospital of Chinese Medical University
    Shenyang, China
  • Zhuzhou Central Hospital
    Zhuzhou, 412007, China
  • Institute of Rheumathology Prague
    Prague, 12850, Czechia
  • Thomayer Hospital
    Praha 4, 14059, Czechia
  • Odense Universitetshospital
    Odense, 5000 C, Denmark
  • Aarhus Universitets Hospital
    Århus, 8000, Denmark
  • HYKS Keuhkosairauksien
    Helsinki, 00290, Finland
  • TYKS, Keuhkosairauksien klinikka, Turku
    Turku, 20520, Finland
  • HOP Avicenne
    Bobigny, 93009, France
  • HOP Louis Pradel
    Bron, 69677, France
  • HOP Calmette
    Lille, 59037, France
  • HOP Claude Huriez
    Lille, 59037, France
  • HOP Arnaud de Villeneuve
    Montpellier, 34295, France
  • HOP Hôtel-Dieu
    Nantes, 44000, France
  • HOP Pasteur
    Nice, 06001, France
  • HOP Cochin
    Paris, 75014, France
  • HOP Bichat
    Paris, 75018, France
  • HOP Pontchaillou
    Rennes, 35033, France
  • HOP Charles Nicolle
    Rouen, 76000, France
  • HOP Larrey
    Toulouse, 31059, France
  • HOP Bretonneau
    Tours, 37044, France
  • Kerckhoff-Klinik, Bad Nauheim
    Bad Nauheim, 61231, Germany
  • Klinik Donaustauf
    Donaustauf, 93093, Germany
  • Universitätsklinikum Carl Gustav Carus Dresden
    Dresden, 01307, Germany
  • Universitätsklinikum Erlangen
    Erlangen, 91054, Germany
  • Universitätsmedizin Greifswald
    Greifswald, 17475, Germany
  • Asklepios Klinik Altona
    Hamburg, 22763, Germany
  • Medizinische Hochschule Hannover
    Hannover, 30625, Germany
  • Thoraxklinik-Heidelberg gGmbH am Universitätsklinikum Heidelberg
    Heidelberg, 69126, Germany

Showing the first 100 of 195 sites across 32 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Denton CP, Goh NS, Humphries SM, Maher TM, Spiera R, Devaraj A, Ho L, Stock C, Erhardt E, Alves M, Wells AU. Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trial. Rheumatology (Oxford). 2023 May 2;62(5):1870-1876. doi: 10.1093/rheumatology/keac535. PubMed 36111858 ↗
  • Maher TM, Bourdin A, Volkmann ER, Vettori S, Distler JHW, Alves M, Stock C, Distler O. Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects. Respir Res. 2022 Jul 5;23(1):178. doi: 10.1186/s12931-022-02095-6. PubMed 35790961 ↗
  • Kreuter M, Hoffmann-Vold AM, Matucci-Cerinic M, Saketkoo LA, Highland KB, Wilson H, Alves M, Erhardt E, Schoof N, Maher TM. Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung disease. Rheumatology (Oxford). 2023 Feb 6;62(SI):SI43-SI53. doi: 10.1093/rheumatology/keac325. PubMed 35640959 ↗
  • Volkmann ER, Kreuter M, Hoffmann-Vold AM, Wijsenbeek M, Smith V, Khanna D, Denton CP, Wuyts WA, Miede C, Alves M, Sambevski S, Allanore Y. Dyspnoea and cough in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial. Rheumatology (Oxford). 2022 Nov 2;61(11):4397-4408. doi: 10.1093/rheumatology/keac091. PubMed 35150246 ↗
  • Kreuter M, Del Galdo F, Miede C, Khanna D, Wuyts WA, Hummers LK, Alves M, Schoof N, Stock C, Allanore Y. Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a joint model analysis. Arthritis Res Ther. 2022 Jan 10;24(1):19. doi: 10.1186/s13075-021-02710-9. PubMed 35012623 ↗
  • Highland KB, Distler O, Kuwana M, Allanore Y, Assassi S, Azuma A, Bourdin A, Denton CP, Distler JHW, Hoffmann-Vold AM, Khanna D, Mayes MD, Raghu G, Vonk MC, Gahlemann M, Clerisme-Beaty E, Girard M, Stowasser S, Zoz D, Maher TM; SENSCIS trial investigators. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. Lancet Respir Med. 2021 Jan;9(1):96-106. doi: 10.1016/S2213-2600(20)30330-1. PubMed 33412120 ↗
  • Roennow A, Sauve M, Welling J, Riggs RJ, Kennedy AT, Galetti I, Brown E, Leite C, Gonzalez A, Portales Guiraud AP, Houyez F, Camp R, Gilbert A, Gahlemann M, Moros L, Luna Flores JL, Schmidt F, Sauter W, Finnern H. Collaboration between patient organisations and a clinical research sponsor in a rare disease condition: learnings from a community advisory board and best practice for future collaborations. BMJ Open. 2020 Dec 16;10(12):e039473. doi: 10.1136/bmjopen-2020-039473. PubMed 33328257 ↗
  • Azuma A, Chung L, Behera D, Chung M, Kondoh Y, Ogura T, Okamoto M, Swarnakar R, Zeng X, Zou H, Meng X, Gahlemann M, Alves M, Kuwana M; SENSCIS trial investigators. Efficacy and safety of nintedanib in Asian patients with systemic sclerosis-associated interstitial lung disease: Subgroup analysis of the SENSCIS trial. Respir Investig. 2021 Mar;59(2):252-259. doi: 10.1016/j.resinv.2020.10.005. Epub 2020 Nov 19. PubMed 33223487 ↗
  • Maher TM, Mayes MD, Kreuter M, Volkmann ER, Aringer M, Castellvi I, Cutolo M, Stock C, Schoof N, Alves M, Raghu G; SENSCIS Trial Investigators. Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol. 2021 Apr;73(4):671-676. doi: 10.1002/art.41576. Epub 2021 Mar 8. PubMed 33142016 ↗
  • Kuwana M, Ogura T, Makino S, Homma S, Kondoh Y, Saito A, Ugai H, Gahlemann M, Takehara K, Azuma A. Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: A Japanese population analysis of the SENSCIS trial. Mod Rheumatol. 2021 Jan;31(1):141-150. doi: 10.1080/14397595.2020.1751402. Epub 2020 Apr 23. PubMed 32243207 ↗
  • Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, Raghu G, Sauter W, Girard M, Alves M, Clerisme-Beaty E, Stowasser S, Tetzlaff K, Kuwana M, Maher TM; SENSCIS Trial Investigators. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med. 2019 Jun 27;380(26):2518-2528. doi: 10.1056/NEJMoa1903076. Epub 2019 May 20. PubMed 31112379 ↗
  • Distler O, Brown KK, Distler JHW, Assassi S, Maher TM, Cottin V, Varga J, Coeck C, Gahlemann M, Sauter W, Schmidt H, Highland KB; SENSCIS trial investigators. Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS). Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 106(4):75-81. Epub 2017 Jun 29. PubMed 28664834 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2015 to primary completion in Oct 2018, 35 months.

Results were first posted in Dec 2019, 1 year 1 month after primary completion.

Of 17 phase 3 interventional studies under Scleroderma, Systemic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 54. This study's 35 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2015
First posted
Nov 5, 2015
StartActual
Nov 12, 2015
Primary completionActual
Oct 31, 2018
CompletionActual
Nov 28, 2018
Results first posted
Dec 13, 2019
Last update
Dec 13, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02597933
Responsible party
Sponsor
First posted
Nov 5, 2015
Start date
Nov 12, 2015
Primary completion
Oct 31, 2018
Completion
Nov 28, 2018
Results posted
Dec 13, 2019
Last update
Dec 13, 2019

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nintedanib

Start the discussion